Vilmorin & Cie - Annual report 2017-2018

Financial INFORMATION 5 ANNUAL REPORT Vilmorin & Cie 172 2017-2018 1.3 - Net values In millions of euros Research costs Development costs Germplasm Software Patents and licenses Brands Other intangible fixed assets Current fixed assets Total 06.30.17 - 313.2 269.4 41.3 27.1 27.8 6.9 2.6 688.3 06.30.18 - 326.5 268.6 34.2 25.3 27.8 6.3 4.0 692.7 2- Further information 2.1 - Internally generated fixed assets In addition to development programs whose evolution is tracked above and in Note 8, movements concerning internally generated fixed assets are as follows: In millions of euros Patents and licenses Software Total 07.01.16 (net value) 1.0 - 1.0 New fixed assets 0.1 - 0.1 Fixed assets taken out - - - Currency translations - - - Reclassifications - - - Provisions for amortization -0.3 - -0.3 06.30.17 (net value) 0.8 - 0.8 New fixed assets 0.1 - 0.1 Fixed assets taken out -0.1 - -0.1 Currency translations - Reclassifications 0.1 - 0.1 Provisions for amortization -0.1 - -0.1 06.30.18 (net value) 0.8 - 0.8 2.2 - Impairment An impairment test was conducted in accordance with the methodology described in Note 1 paragraph 11 of “Accounting methods and principles in IFRS standards.” The evolution is as follows: In millions of euros Software Patents and licenses Germplasm Brands Other intangible fixed assets Total 07.01.16 0.3 5.9 0.4 5.8 - 12.4 Fiscal year 16-17 0.6 0.2 - 2.5 - 3.3 06.30.17 0.9 6.1 0.4 8.3 - 15.7 Fiscal year 17-18 - -0.4 - - - -0.4 06.30.18 0.9 5.7 0.4 8.3 - 15.3 As stipulated in Note 1 paragraph 9.4 of “Accounting methods and principles in IFRS standards,” germplasm is tested in the CGU to which it belongs in the case of goodwill impairment tests. Consequently, hypotheses are set out in detail in Note 14. 5.1. Consolidated Financial Statements